Table 3.
Stratified analyses by age, sex, cancer localization and stage of disease. Subgroup analyses excluding or restricting to certain populations.
| Cases Exposed/unexposed | Controls Exposed/unexposed | Crude OR | Adjusted OR † | |
|---|---|---|---|---|
| All | 674 / 19,207 | 7,724 / 189,540 | 0.86 (0.79–0.93) | 0.89 (0.81–0.96) |
| Age | ||||
| <50 years | 10 / 872 | 141 / 8,341 | 0.69 (0.36–1.32) | 0.68 (0.35–1.31) |
| 50–69 years | 242 / 8,651 | 2,761 / 85,238 | 0.86 (0.75–0.98) | 0.87 (0.76–1.00) |
| 70+ years | 422 / 9,684 | 4,822 / 95,961 | 0.87 (0.78–0.96) | 0.90 (0.81–1.01) |
| Sex | ||||
| Male | 334 / 11,083 | 3,787 / 109,983 | 0.88 (0.79–0.99) | 0.89 (0.79–1.00) |
| Female | 340 / 8,124 | 3,937 / 79,557 | 0.84 (0.75–0.94) | 0.89 (0.79–1.00) |
| Localization | ||||
| Proximal | 236 / 5,377 | 2,400 / 54,110 | 0.98 (0.86–1.13) | 0.98 (0.85–1.13) |
| Distal | 206 / 6,122 | 2,408 / 60,178 | 0.84 (0.73–0.98) | 0.87 (0.75–1.01) |
| Rectum | 202 / 6,971 | 2,575 / 67,907 | 0.77 (0.66–0.89) | 0.81 (0.70–0.94) |
| Unknown | 30 / 737 | 341 / 7,345 | 0.83 (0.56–1.23) | 0.82 (0.55–1.23) |
| Stage of disease | ||||
| Localized | 240 / 6,649 | 2,781 / 66,597 | 0.86 (0.75–0.99) | 0.84 (0.73–0.96) |
| Non-localized | 304 / 9,170 | 3,554 / 89,739 | 0.84 (0.74–0.94) | 0.91 (0.81–1.03) |
| Unknown | 130 / 3,388 | 1,389 / 33,204 | 0.92 (0.76–1.11) | 0.92 (0.76–1.11) |
|
Other subgroups | ||||
| Excluding lithium exposed | 581 / 19,185 | 6,856 / 189,327 | 0.83 (0.76–0.91) | 0.85 (0.78–0.93) |
| Excluding diabetics | 561 / 17,665 | 6,537 / 176,156 | 0.85 (0.78–0.94) | 0.89 (0.82–0.98) |
| Excluding alcohol abusers | 605 / 18,337 | 6,885 / 182,072 | 0.87 (0.80–0.95) | 0.91 (0.83–0.99) |
| Excluding NSAID exposed (≥1 prescription) | 173 / 9,583 | 1,439 / 92,782 | 1.26 (1.05–1.50) | 1.26 (1.05–1.51) |
| Excluding NSAID exposed (≥3 prescriptions) | 228 / 11,861 | 1,939 / 114,644 | 1.20 (1.04–1.40) | 1.21 (1.04–1.41) |
| Excluding ASA exposed | 419 / 14,536 | 4,529 / 142,885 | 0.91 (0.82–1.01) | 0.93 (0.84–1.04) |
| Excluding NSAID & ASA users (≥1 prescription) | 477 / 16,559 | 5,073 / 162,174 | 0.92 (0.83–1.01) | 0.94 (0.85–1.04) |
| Restricting to NSAID users | 501 / 9,624 | 6,285 / 96,758 | 0.81 (0.73–0.90) | 0.83 (0.75–0.92) |
| Restricting to ASA users | 255 / 4,671 | 3,195 / 46,655 | 0.77 (0.66–0.90) | 0.80 (0.68–0.94) |
| Restricting to diabetics | 113 / 1,542 | 1,187 / 13,384 | 0.75 (0.52–1.09) | 0.80 (0.55–1.17) |
| Restricting to alcohol abusers | 69 / 870 | 839 / 7,468 | 0.78 (0.43–1.42) | 0.93 (0.49–1.77) |
| Restricting to lithium users | 581 / 19,185 | 6,856 / 189,327 | 0.83 (0.76–0.91) | 0.85 (0.78–0.93) |
| Restricting to those sampled 2004–2009 | 162 / 4,409 | 1,771 / 43,615 | 0.88 (0.75–1.04) | 0.90 (0.76–1.06) |
| Restricting to those sampled 2010–2015 | 512 / 14,798 | 5,953 / 145,925 | 0.85 (0.78–0.94) | 0.88 (0.80–0.97) |
†
Fully adjusted model included following drugs and diagnoses: statins, antidepressants, hormone replacement therapy, NSAIDs, ASA, diabetes, chronic obstructive pulmonary disease, and alcohol-related disease, highest achieved education